Pius-Hospital Oldenburg
- Address
- lock Available on a paid plan
Pius-Hospital Oldenburg - Advanced Thoracic Oncology and Hematology Research Center
Pius-Hospital Oldenburg is a leading clinical research center specializing in comprehensive oncology trials with particular expertise in thoracic malignancies and hematologic disorders. The center demonstrates exceptional capabilities in conducting complex Phase II and III studies across multiple cancer types, with a strong emphasis on precision medicine and biomarker-driven therapeutic approaches.
- Advanced Non-Small Cell Lung Cancer (NSCLC) with focus on targeted therapies for EGFR, ALK, ROS1, KRAS, and HER2 mutations
- Small Cell Lung Cancer (SCLC) including extensive-stage disease and immunotherapy combinations
- Hematologic Malignancies including Acute Myeloid Leukemia (AML), Lymphomas (Follicular, Primary CNS, Hodgkin, and Marginal Zone), and innovative stem cell transplantation protocols
- Colorectal and Rectal Cancer with emphasis on neoadjuvant strategies and organ preservation approaches
The center excels in evaluating novel immunotherapy combinations, including checkpoint inhibitors like durvalumab, pembrolizumab, and atezolizumab, alongside conventional chemotherapy and radiation therapy. Research efforts emphasize personalized treatment strategies utilizing liquid biopsy monitoring (ctDNA analysis), PET-based imaging guidance, and genomic profiling. The facility actively participates in cutting-edge trials investigating antibody-drug conjugates, targeted kinase inhibitors, and multimodal treatment approaches incorporating surgery, radiotherapy, and systemic therapy. With expertise spanning both adult and pediatric populations, Pius-Hospital Oldenburg contributes significantly to advancing cancer care through rigorous clinical investigation of emerging therapeutics and treatment optimization strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 90 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 87 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Boehringer Ingelheim Espana S.A.3active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pius-Hospital Oldenburg
lock Showing 1 of 55 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867) | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jun 2019 | Aug 2024 |
IMP list
lock Showing 1 of 90 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 20 | Unknown | 2018-04-04 | 2026-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.